GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Inventories, Work In Process

Curocell (XKRX:372320) Inventories, Work In Process : ₩0.00 Mil (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Curocell Inventories, Work In Process?

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Curocell's work in process for the quarter that ended in Jun. 2023 was ₩0.00 Mil.


Curocell Inventories, Work In Process Historical Data

The historical data trend for Curocell's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Inventories, Work In Process Chart

Curocell Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Work In Process
- - - - -

Curocell Semi-Annual Data
Jun22 Dec22 Jun23 Dec23
Inventories, Work In Process - - - -

Curocell Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.


Curocell (XKRX:372320) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002
Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell (XKRX:372320) Headlines

No Headlines